A 6-month-old infant in Mumbai presents with fever, cough, and respiratory distress. The child had received BCG vaccine at birth but the immunization record is unavailable. The pediatrician suspects disseminated BCG disease (BCG-itis). Which investigation is most appropriate to confirm BCG strain identification and rule out Mycobacterium tuberculosis infection?

Explanation

## Confirmation of BCG Strain vs. M. tuberculosis in Disseminated Mycobacterial Disease ### Mycobacterial Culture with Biochemical Identification **Key Point:** Culture on Löwenstein–Jensen medium followed by biochemical tests (niacin accumulation test and nitrate reduction test) is the gold standard for differentiating BCG from M. tuberculosis and other mycobacterial species. **High-Yield:** BCG is a live attenuated vaccine strain derived from M. bovis. It is biochemically distinct from M. tuberculosis and can be definitively identified through culture and biochemical testing. ### Biochemical Differentiation: BCG vs. M. tuberculosis | Test | M. tuberculosis | BCG (M. bovis) | |------|-----------------|----------------| | **Niacin accumulation test** | Positive (niacin accumulates in culture filtrate) | Negative (niacin-negative) | | **Nitrate reduction test** | Positive (reduces nitrate to nitrite) | Negative (nitrate-negative) | | **Pyrazinamidase activity** | Positive (resistant to pyrazinamide) | Negative (susceptible to pyrazinamide) | | **Glycerol preference** | Glycerol-preferring (eugonic on glycerol-containing media) | Glycerol-inhibited (dysgonic on glycerol media) | **Clinical Pearl:** BCG-itis (disseminated BCG disease) is a rare complication in immunocompromised infants (e.g., severe combined immunodeficiency, HIV infection). Culture identification is essential because BCG is susceptible to pyrazinamide, whereas M. tuberculosis is intrinsically resistant. ### Investigation Protocol for Suspected Disseminated BCG Disease 1. **Specimen collection** — Gastric aspirate (higher yield in infants), sputum, CSF, lymph node biopsy, or blood culture 2. **AFB smear microscopy** — Rapid screening but non-specific 3. **Culture on Löwenstein–Jensen medium** — Slow-growing (2–8 weeks) but gold standard 4. **Biochemical tests** — Niacin test and nitrate reduction test on isolated colonies 5. **Drug susceptibility testing** — Essential to guide therapy (pyrazinamide sensitivity distinguishes BCG from TB) **Mnemonic: NITRA** — Niacin test, Nitrate reduction, Tuberculin sensitivity, Reduction of nitrate, Accumulation of niacin (for M. tuberculosis identification). ### Why Culture + Biochemical Testing is the Investigation of Choice - **Definitive identification** — Distinguishes BCG from M. tuberculosis and other mycobacteria - **Guides therapy** — BCG is pyrazinamide-susceptible; M. tuberculosis is resistant - **Gold standard** — WHO-endorsed method for mycobacterial species identification - **Prognostic value** — Confirms vaccine-strain disease vs. wild-type TB [cite:Park 26e Ch 7; Robbins 10e Ch 8] ### Why Other Investigations Are Inappropriate While AFB smear microscopy is rapid, it cannot differentiate BCG from M. tuberculosis. The Mantoux test will be positive in both cases (BCG vaccination and TB infection). Imaging studies are non-specific and cannot identify the organism.